Systemic Lupus Erythematosus and Lupus Nephritis Epidemiology Analysis and Forecast to 2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Systemic Lupus Erythematosus and Lupus Nephritis Market Report Overview
The diagnosed incident cases of Systemic Lupus Erythematosus (SLE) were 36,601 in the seven major markets (7MM) in 2021 and are expected to achieve an AGR of less than 1%. Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a chronic relapsing and remitting course, having variable manifestations ranging from mild to life-threatening illness (Tsokos, 2011). In SLE, the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. The diagnosed incident cases of Lupus Nephritis (LN) were 5,065 in the seven major markets (7MM) in 2021 and are expected to achieve an AGR of less than 1%.
Systemic Lupus Erythematosus Market Outlook, 2021-2031 (Diagnosed Incident Cases)
For more insights into the Systemic Lupus Erythematosus and Lupus Nephritis market forecast, download a free report sample
Among SLE patients, one-third to almost half have renal manifestation, referred to as lupus nephritis (LN). LN is one of the most serious complications of SLE. LN occurs when lupus autoantibodies affect structures in the kidneys that filter out waste. This causes kidney inflammation and may lead to blood in the urine, protein in the urine, high blood pressure, weight gain, swollen ankles, impaired kidney function, or even kidney failure.
Lupus Nephritis Market Outlook, 2021-2031 (Diagnosed Incident Cases)
For more insights into the Systemic Lupus Erythematosus and Lupus Nephritis market forecast, download a free report sample
The SLE and LN market research report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for SLE and LN in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report also includes a 10-year epidemiology forecast for the diagnosed incident cases and diagnosed incident cases of both SLE and LN.
Market Size (2021) (SLE) | 36,601 cases |
Market Size (2021) (LN) | 5,065 cases |
AGR (2021-2031) (SLE and LN) | <1% |
Key Age Segments (SLE and LN) | 0-9 years, 10-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years or above |
Key Sex Segments (SLE and LN) | Men and Women |
Systemic Lupus Erythematosus and Lupus Nephritis Market Segmentation by Age
Based on age, the SLE and LN market can be segmented into 0-9 years, 10-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years or above.
In 2021, for the 7MM combined, the 50–59 year age group contributed the highest proportion of the diagnosed incident cases of SLE , followed by the age group 40–49 years and ages 30–39 years.
In 2021, for the 7MM combined, the 30–39 year age group contributed the highest proportion of the diagnosed incident cases of LN , followed by the age group 40–49 years and ages 50–59 years.
Systemic Lupus Erythematosus Market Analysis, by Age, 2021 (%)
For more age segment insights into the Systemic Lupus Erythematosus and Lupus Nephritis market, download a free report sample
Systemic Lupus Erythematosus and Lupus Nephritis Market Segmentation by Sex
In 2021, the number of diagnosed incident cases of SLE and LN was higher in women than in men in the 7MM combined. Among the 7MM, Japan had the largest difference in the diagnosed incident cases of SLE between women and men, and Spain had the smallest variation.
In 2021, among men the diagnosed prevalence of SLE was highest in Spain and the UK, followed by Germany, and was lowest in the US, France, Italy, and Japan. In 2021, among women, the diagnosed prevalence of SLE was highest in Spain, followed by the UK and the US, and was lowest in Italy.
Systemic Lupus Erythematosus Market Analysis, by Sex, 2021 (%)
For more sex segment insights into the Systemic Lupus Erythematosus and Lupus Nephritis market, download a free report sample
Scope
- The diagnosed incident cases of SLE and LN, and the diagnosed prevalent cases of SLE, are segmented by age (in five-year age-groups) and sex.
- The report includes the diagnosed prevalent cases of SLE by severity (uncomplicated SLE [mild] and complicated SLE [moderate/severe]], and the diagnosed prevalent cases of LN segmented by severity based on the 2003 International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification (class I, class II, class III, class IV, class V, and class VI). Additionally, diagnosed prevalent cases of LN are segmented by treatment received. This epidemiology forecast for SLE and LN is supported by data obtained from peer-reviewed articles and population-based studies.
- The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast diagnosed incident cases and prevalent cases and diagnosed prevalent cases of SLE and LN across these markets.
Reasons to Buy
The SLE and LN epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global SLE and LN market.
- Quantify patient populations in the global SLE and LN market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for SLE and LN therapeutics in each of the markets covered.
Table of Contents
Table
Figures
Frequently asked questions
-
How many diagnosed incident cases of Systemic Lupus Erythematosus (SLE) were seen in the 7MM in 2021?
In 2021, 36,601 diagnosed incident cases of Systemic Lupus Erythematosus (SLE) were seen in the seven major markets (7MM).
-
How many diagnosed incident cases of Lupus Nephritis (LN) were seen in the 7MM in 2021?
In 2021, 5,065 diagnosed incident cases of Lupus Nephritis (LN) were seen in the seven major markets (7MM).
-
What is the growth rate of the Systemic Lupus Erythematosus and Lupus Nephritis market?
The cases are expected to achieve an AGR of less than 1% during the period 2021-2031.
-
What are the key age segments in the Systemic Lupus Erythematosus and Lupus Nephritis market?
The key age segments in the Systemic Lupus Erythematosus and Lupus Nephritis market are 0-9 years, 10-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years or above.
-
Which sex segment has the highest incidences of Systemic Lupus Erythematosus and Lupus Nephritis?
The number of diagnosed incident cases of SLE and LN was higher in women than in men in the 7MM combined in 2021.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.